【摘要】 目的：观察补肾化瘀方对肾虚血瘀型多囊卵巢综合征（polycystic ovarian syndrome,PCOS患者血清性激素水平及低氧诱导因子1α(hypoxia inducible factor-1α,HIF-1α)、肌球蛋白样BCL2结合蛋白（myosin-like BCL2 interacting protein,Beclin-1）、腺病毒E1B相互作用蛋白3(adenovirus E1B 19kDa protein-interacting protein 3,BNIP3)的影响。方法：将肾虚血瘀型PCOS患者100例，按随机数字表法分为对照组和治疗组各50例。对照组予达英-35治疗，治疗组予补肾化瘀方治疗，两组均连续治疗3个月。比较两组患者治疗前后血清卵泡刺激素（follicle-stimulating hormone,FSH）、促黄体生成素（luteinizing hormone,LH）、睾酮（testosterone,T）、泌乳素（prolactin,PRL）、雌二醇（estradiol,E2）、孕酮（progesterone,P）的表达水平及HIF-1α、Beclin、BNIP3 mRNA表达水平。结果：治疗后两组患者血清LH、FSH、E2、T、P表达水平均降低，PRL表达水平升高（P<0.05），治疗组改善程度优于对照组（P<0.05）;HIF-1α、Beclin-1、BNIP3 mRNA表达水平均降低（P<0.05），治疗组降低更明显（P<0.05）。结论：补肾化瘀方能够改善肾虚血瘀型PCOS患者血清性激素表达水平，其可能在自噬调控中发挥作用，进而改善PCOS患者临床症状。更多还原

【Abstract】 Objective: To observe the effects of kidney-tonifying stasis-removing formula on the levels of serum sex hormone, HIF-1α, Beclin-1 and BNIP3 in patients with polycystic ovarian syndrome(PCOS) of kidney deficiency and blood stasis pattern. Methods: All 100 cases of PCOS of kidney deficiency and blood stasis pattern were divided into the control group and the treatment group according to random number table method with 50cases in each group. The control group was treated with ethinylestradiol and cyproterone acetate tablets, and the treatment group took the formula, and both groups were treated for three months continuously. To compare the expressions of FSH, LH, T, PRL, E2 and P, as well as the levels of HIF-1α, Beclin-1 and BNIP3 mRNA before and after the treatment between the two groups. Results: After the treatment, the expressions of LH, FSH, E2, T and P were lowered, and the levels of PRL were raised(P<0.05), the improvements of the treatment group were better than these of the control group(P<0.05); the expressions of HIF-1α, Beclin-1 and BNIP3 mRNA were lowered(P<0.05), and the decrease of the treatment group was more apparent(P<0.05). Conclusion: Kidney-tonifying stasis-removing formula could improve the levels of serum sex hormone, which might play the role in regulating the autophagy, thereby mitigating the patients’ clinical symptoms.更多还原